Related Experiment Video

Updated: Jul 9, 2026

A Technique to Simultaneously Visualize Virus-Specific CD8+ T Cells and Virus-Infected Cells In situ
20:47

A Technique to Simultaneously Visualize Virus-Specific CD8+ T Cells and Virus-Infected Cells In situ

Published on: August 13, 2009

Helmut Ruska and the visualisation of viruses

D H Kruger1, P Schneck, H R Gelderblom

  • 1Department of Virology, Charité Medical School, Humboldt University, Berlin, Germany. detlev.kruger@charite.de

Lancet (London, England)
|July 25, 2000
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Alphavirus Transducing System: Tools for Visualizing Infection in Mosquito Vectors
07:12

Alphavirus Transducing System: Tools for Visualizing Infection in Mosquito Vectors

Published on: November 24, 2010

Visualizing Dengue Virus through Alexa Fluor Labeling
09:11

Visualizing Dengue Virus through Alexa Fluor Labeling

Published on: July 9, 2011

Related Experiment Videos

Last Updated: Jul 9, 2026

A Technique to Simultaneously Visualize Virus-Specific CD8+ T Cells and Virus-Infected Cells In situ
20:47

A Technique to Simultaneously Visualize Virus-Specific CD8+ T Cells and Virus-Infected Cells In situ

Published on: August 13, 2009

Alphavirus Transducing System: Tools for Visualizing Infection in Mosquito Vectors
07:12

Alphavirus Transducing System: Tools for Visualizing Infection in Mosquito Vectors

Published on: November 24, 2010

Visualizing Dengue Virus through Alexa Fluor Labeling
09:11

Visualizing Dengue Virus through Alexa Fluor Labeling

Published on: July 9, 2011

Related Concept Videos

What are Viruses?00:50

What are Viruses?

Overview
Introduction to Virus01:28

Introduction to Virus

Viruses are unique biological entities that blur the boundary between living and non-living systems. Although they lack cellular structure and metabolic processes, they can exhibit characteristics of life when infecting a host. Their defining feature is a nucleic acid core, composed of either DNA or RNA, encapsulated within a protein coat called a capsid. This simple structure allows them to invade host cells and use their machinery for replication efficiently.Viral Structure and...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...

Articles linked to this work by shared authors, journal, and citation graph.

Hantavirus disease in Germany due to infection with Dobrava-Belgrade virus genotype Kurkino.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2014

Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection.

Medical microbiology and immunology·2013

The broad spectrum of hantaviruses and their hosts in Central Europe.

Acta virologica·2013

Performance of the MagNA Pure 96 system for cytomegalovirus nucleic acid amplification testing in clinical samples.

Journal of clinical microbiology·2013

[From mice to men - insights from the hantavirus epidemic in 2010].

Deutsche medizinische Wochenschrift (1946)·2012

Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines.

Medical microbiology and immunology·2012

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Ocular mpox in Southern Nigeria during the 2022 and 2024 outbreaks: a report of two cases.

The Pan African medical journal·2026

Measuring vancomycin using paired pulse voltammetry with a wireless instantaneous neurotransmitter concentration sensing system for point-of-care patient treatment.

Biomedical engineering letters·2026

MERS-CoV in the Middle East and Africa: from surveillance gaps in humans and dromedary camels to One Health frameworks for spillover, prevention, research and response preparedness.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026

Disseminated Histoplasmosis: The Great Mimicker in Patients With Advanced HIV Disease.

Cureus·2026

Now you see me, now you don't: A vanishing papillomatous CMV pseudotumor in an immunocompetent host.

IDCases·2026

Case Report: Presumed ocular tuberculosis masquerading as acute retinal necrosis: the diagnostic and therapeutic journey of an elderly female.

Frontiers in medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us